Bryan Johnson Peptide Protocol — What He Actually Takes

Bryan Johnson's publicly documented longevity protocol includes three peptides with specific biological targets: Epithalon (a synthetic tetrapeptide that modulates telomerase activity), BPC-157 (a gastric peptide analogue with tissue repair properties documented in animal models), and Thymalin (a thymic peptide that supports immune function regulation). Our team has reviewed the published research behind each compound, the dosing protocols Johnson himself has referenced, and the practical constraints researchers face when working with these molecules. The gap between the marketed version of his protocol and the actual implementation details matters. Peptide purity, reconstitution method, and injection timing can each independently determine whether a given dose produces the intended effect.

We've worked with hundreds of research teams implementing peptide protocols at the lab-bench level. The difference between doing it right and treating peptides like dietary supplements comes down to three things most popular accounts of Johnson's protocol never mention: storage discipline after reconstitution, injection site rotation strategy, and baseline biomarker tracking before starting any peptide intervention.

What peptides does Bryan Johnson use in his longevity protocol?

Bryan Johnson's documented peptide regimen centers on three compounds: Epithalon (administered in 10mg cycles for telomere maintenance), BPC-157 (dosed at 250–500mcg daily for connective tissue support), and Thymalin (used in 10mg cycles for thymic peptide support). Each peptide targets a distinct biological pathway. Telomerase activation, tissue remodeling signaling, and immune system calibration respectively. The protocol is structured in cycles rather than continuous administration, with each peptide following a specific on/off schedule tied to its mechanism of action and half-life.

Direct Answer: The Three Core Peptides

Most articles reduce Johnson's protocol to a list of brand names and wellness marketing. That misses the mechanism. Epithalon works by binding to chromatin in cell nuclei and upregulating telomerase expression. The enzyme that rebuilds telomere length after cellular replication. BPC-157 is a synthetic gastric peptide derived from a protective protein in human gastric juice; it promotes angiogenesis and modulates growth factor activity in damaged tissue. Thymalin is a thymic extract containing bioregulatory peptides that restore T-cell differentiation in aging immune systems. This article covers the specific dosing protocols Johnson follows, the research foundation for each peptide's claimed effects, and the practical preparation requirements that determine whether a peptide protocol delivers measurable results or becomes an expensive placebo.

Why Peptides Anchor Johnson's Longevity Protocol

Bryan Johnson positions peptides as the molecular foundation of his Blueprint protocol because they act at the regulatory level. Not as metabolic fuels or antioxidant buffers, but as signaling molecules that directly influence gene expression, protein synthesis rates, and cellular repair pathways. Epithalon modulates the pineal gland's melatonin production cycle while simultaneously activating telomerase in peripheral tissues. A dual mechanism no small-molecule supplement replicates. BPC-157's mechanism involves upregulation of vascular endothelial growth factor (VEGF) receptors, accelerating capillary formation in damaged tissue and reducing inflammatory cytokine cascades at injury sites. Thymalin restores thymic peptide signaling that declines after age 25, when the thymus begins involuting and T-cell diversity starts narrowing.

The protocol Johnson follows is not continuous dosing. It's structured in 10-day to 20-day cycles with defined rest periods. Epithalon is administered in 10mg cycles over 10–20 days, repeated every 3–6 months. BPC-157 runs in shorter 4–6 week cycles at 250–500mcg daily, typically timed around periods of high physical training load or injury recovery. Thymalin follows a 10-day cycle of 10mg subcutaneous injections, repeated quarterly. The cyclical structure reflects peptide pharmacokinetics. Continuous administration can lead to receptor downregulation, where target cells reduce receptor density in response to prolonged signaling, diminishing the peptide's effect over time.

Our experience working with research peptide protocols shows the same pattern: dose cycling consistently outperforms continuous administration for signaling peptides. The rest periods allow receptor density to normalize and prevent the adaptive dampening that makes many peptide interventions lose potency after 6–8 weeks of uninterrupted use.

The Research Foundation Behind Each Peptide

Epithalon's mechanism was characterized in studies conducted at the St. Petersburg Institute of Bioregulation and Gerontology, where researchers demonstrated that 10mg subcutaneous injections over 10 days increased mean telomere length in human peripheral blood lymphocytes by 33% compared to baseline measurements. The peptide's sequence (Ala-Glu-Asp-Gly) mimics epithalamin, a pineal gland extract shown in animal models to extend lifespan by 25–40% in mice and rats. The human data is more limited. A 2003 study in Bulletin of Experimental Biology and Medicine reported that Epithalon administration reduced all-cause mortality rates in elderly patients over a 12-year follow-up period, though the study design (non-randomized, observational cohort) limits causal inference.

BPC-157's tissue repair effects are documented primarily in rodent models. A 2018 study in the Journal of Physiology and Pharmacology showed that BPC-157 accelerated Achilles tendon healing in rats by 72% compared to saline controls, measured via biomechanical tensile strength testing at 14 days post-injury. The peptide's mechanism involves activation of the FAK-paxillin pathway, which regulates cytoskeletal organization during tissue remodeling. Human trials are sparse. The existing evidence base relies on animal models, case reports, and mechanistic studies in cultured human cell lines. Johnson's use of BPC-157 reflects adoption of a compound with strong preclinical data but limited Phase III clinical validation.

Thymalin restores thymic peptide signaling that naturally declines with age. A study published in the Annals of the New York Academy of Sciences found that thymic peptide administration in elderly patients increased CD4+ T-cell counts by 43% and improved antibody responses to influenza vaccination by 38% compared to placebo. The thymus reaches maximum size around puberty, then undergoes progressive involution. By age 60, functional thymic tissue has declined by more than 90%. Thymalin provides bioregulatory peptides normally secreted by thymic epithelial cells, partially compensating for this age-related decline.

Reconstitution and Storage: Where Most Protocols Fail

Here's the honest answer: most peptide protocols fail before the first injection. At the reconstitution and storage stage. Lyophilized peptides (the powdered form shipped by research suppliers) are stable at −20°C for 12–24 months, but once reconstituted with bacteriostatic water, stability drops to 28 days under refrigeration at 2–8°C. Any temperature excursion above 8°C triggers irreversible protein denaturation. The peptide's three-dimensional structure unfolds, eliminating biological activity without changing its visual appearance. A vial that spent 6 hours at room temperature during shipping looks identical to a properly stored vial but contains zero active compound.

Reconstitution technique matters as much as storage. The standard error is injecting air into the vial while drawing bacteriostatic water. The resulting positive pressure inside the vial pulls contaminants backward through the needle on every subsequent draw, introducing bacterial contamination that bacteriostatic water cannot fully suppress. The correct method: use a separate sterile needle to vent the vial (allowing air to escape as liquid enters), then inject bacteriostatic water slowly down the inside wall of the vial rather than directly onto the lyophilized powder. Direct injection onto the powder can denature peptides through mechanical shear stress.

Johnson's team reportedly uses pharmaceutical-grade peptides synthesized under cGMP standards and stored in medical-grade refrigeration with continuous temperature logging. That level of infrastructure is not typical for individual researchers. Most peptide degradation in research settings occurs during the 28-day post-reconstitution window. A vial stored in a household refrigerator with a door opened 15 times per day experiences cumulative thermal stress that measurably reduces peptide potency by day 21, even if the displayed temperature never exceeds 4°C.

Comparison: Bryan Johnson's Peptide Protocol vs Standard Research Approaches

Key Takeaways

• Bryan Johnson's peptide protocol uses Epithalon for telomerase activation, BPC-157 for tissue repair, and Thymalin for immune system support. Each targeting distinct biological pathways documented in preclinical research.
• Epithalon is administered in 10mg cycles over 10–20 days every 3–6 months, based on studies showing increased telomere length in human lymphocytes after 10-day administration.
• BPC-157 dosing at 250–500mcg daily for 4–6 weeks aligns with rodent-to-human conversion factors and is typically cycled around periods of high training load or injury recovery.
• Reconstituted peptides remain stable for only 28 days at 2–8°C. Temperature excursions above 8°C cause irreversible protein denaturation that eliminates biological activity without visible change.
• Peptide protocols require baseline biomarker tracking (telomere length via qPCR, inflammatory markers, immune cell counts) to distinguish placebo effects from measurable biological outcomes.
• Continuous peptide administration leads to receptor downregulation. Cyclical protocols with defined rest periods maintain receptor sensitivity and prevent adaptive dampening of the peptide's effect.

What If: Bryan Johnson Peptide Protocol Scenarios

What If I Miss a Dose During a 10-Day Epithalon Cycle?

Administer the missed dose as soon as you remember if fewer than 12 hours have passed, then continue the regular schedule. If more than 12 hours have passed, skip the missed dose entirely and resume on the next scheduled day. Do not double-dose to compensate. Missing a single dose in a 10-day cycle reduces cumulative exposure by 10% but does not eliminate the protocol's effect. The telomerase activation mechanism accumulates over the full cycle rather than depending on each individual dose.

What If Reconstituted Peptide Was Left at Room Temperature Overnight?

Discard the vial. Peptides stored above 8°C for more than 2 hours undergo progressive denaturation. The rate depends on the specific peptide's structural stability, but for most research peptides, 8 hours at 20–25°C eliminates 60–90% of biological activity. Denatured peptide cannot be restored through re-refrigeration. Visual inspection is unreliable. A denatured peptide solution looks identical to a properly stored one. The financial loss from discarding a compromised vial is smaller than the biological cost of injecting an inactive compound while believing it is producing effects.

What If I Want to Track Whether the Peptides Are Working?

Baseline biomarker testing before starting any peptide protocol is essential. For Epithalon, measure telomere length via quantitative PCR (qPCR) testing at baseline and again 3–6 months after completing a cycle. Telomere length changes are detectable but require specialized lab assays not available through standard blood panels. For BPC-157, track inflammatory markers (hsCRP, IL-6) and subjective pain scores if using it for injury recovery. For Thymalin, measure CD4+ and CD8+ T-cell counts, NK cell activity, and IgG antibody titers. Without baseline data, distinguishing placebo effects from biological changes is impossible. Peptide protocols produce subtle shifts in regulatory pathways, not the acute symptom changes typical of pharmaceutical drugs.

The Uncomfortable Truth About Peptide Longevity Protocols

Let's be direct about this: the evidence supporting peptides as longevity interventions in humans is thin. The published human data consists mostly of small Eastern European trials from the 1990s and early 2000s, observational cohorts with selection bias, and mechanistic studies in cell culture. Epithalon's telomere-lengthening effects are demonstrated in human cells but the link between telomere length and functional lifespan extension remains contested. Some gerontology researchers argue telomere attrition is a marker of aging rather than a cause. BPC-157 has never completed a Phase III randomized controlled trial in humans. Thymalin's immune-boosting effects are real but whether restoring youthful T-cell counts translates to reduced all-cause mortality is speculative.

Bryan Johnson's approach treats his own body as an N-of-1 clinical trial with continuous biomarker tracking, physician oversight, and controlled variables most people cannot replicate. The peptide protocol he follows is not validated by FDA approval, consensus guidelines from gerontology societies, or longitudinal cohort data showing lifespan extension. It represents aggressive adoption of preclinical research findings based on mechanistic plausibility and personal risk tolerance. That doesn't make it wrong. It makes it experimental. Anyone considering a similar protocol should frame it as participation in self-directed research, not implementation of a proven intervention.

How Peptide Purity Affects Biological Outcomes

The peptide supply chain introduces variability that matters. Research-grade peptides are synthesized via solid-phase peptide synthesis (SPPS), purified through high-performance liquid chromatography (HPLC), and verified via mass spectrometry to confirm amino acid sequence accuracy and purity percentage. A peptide labeled 98% pure contains 2% contaminants. Truncated sequences, deletion peptides, or synthesis byproducts that can trigger immune responses or block receptor binding without producing the intended biological effect.

Johnson's team reportedly sources peptides from cGMP-certified synthesis facilities that provide Certificates of Analysis (CoA) documenting purity via HPLC chromatograms and mass spec verification. Most consumer peptide suppliers do not provide this level of documentation. Peptides sold through wellness channels or gray-market research chemical vendors frequently test below their labeled purity when independently assayed. A 2019 analysis published in the Journal of Pharmaceutical and Biomedical Analysis found that 34% of peptides purchased from non-pharmaceutical suppliers contained less than 90% of the stated active compound.

Purity gaps compound over a multi-month protocol. A peptide cycle using 95% pure Epithalon delivers 5% less active compound per injection than a 99% pure preparation. Over a 10-day cycle at 10mg daily, that's a cumulative 5mg difference in total exposure. For peptides with steep dose-response curves, that difference can shift the protocol from sub-threshold to therapeutic dosing. Our team works exclusively with peptides that include third-party purity verification. The cost premium (typically 20–40% over unverified sources) is justified by the elimination of dosing uncertainty.

Injection Technique and Site Rotation Strategy

Subcutaneous injection technique affects peptide absorption kinetics. The standard injection sites. Abdomen 2 inches lateral to the umbilicus, anterior thigh, or upper outer arm. Have different subcutaneous fat thicknesses and capillary densities, which influence absorption rates. Abdominal injections typically show 10–15% faster absorption than thigh injections due to higher local blood flow. Johnson's protocol specifies abdominal subcutaneous injection for all three peptides, administered in the morning after fasting bloodwork.

Site rotation prevents lipohypertrophy. Localized fat tissue proliferation caused by repeated insulin or peptide injections in the same anatomical location. Injecting the same 2cm² area more than twice per week triggers adipocyte hyperplasia and fibrotic tissue formation, creating nodules that reduce subsequent injection absorption by up to 30%. The rotation strategy: divide the abdominal injection zone into 8 quadrants (4 per side), cycling through each quadrant before returning to the first. For a 10-day Epithalon cycle with daily injections, this means using each site once with two sites used twice.

Injection depth matters for peptides with low molecular weight. BPC-157 (molecular weight 1,419 Da) and Epithalon (390 Da) are small enough to cross from subcutaneous tissue into systemic circulation rapidly, but injecting too shallow. Into the dermis rather than the subcutaneous layer. Causes localized irritation and reduces bioavailability. The correct technique uses a 29-gauge insulin syringe with a 0.5-inch needle, inserted at 90 degrees to the skin surface, with a pinched skin fold to ensure subcutaneous placement. Aspiration (pulling back on the plunger to check for blood) is not necessary for subcutaneous injections and increases contamination risk.

The Reality Check: What Johnson's Protocol Costs

A single Epithalon cycle (10mg daily for 10–20 days) requires 100–200mg total. At research-grade prices with purity verification, that's $280–$450 per cycle. BPC-157 at 500mcg daily for 6 weeks requires 21mg total, costing approximately $190–$240 per cycle. Thymalin at 10mg daily for 10 days costs $320–$400 per cycle. Running all three peptides on Johnson's documented schedule. Epithalon twice yearly, BPC-157 as needed (average 2–3 cycles/year), Thymalin quarterly. Totals $2,800–$3,600 annually in peptide costs alone.

That excludes the infrastructure: pharmaceutical-grade bacteriostatic water ($15–$25 per 30mL vial), sterile syringes ($0.40–$0.60 each × 150–200 injections/year), alcohol prep pads, sharps disposal containers, and baseline biomarker testing (telomere length qPCR: $200–$350; comprehensive immune panel: $180–$280; inflammatory markers: $90–$150). Total annual protocol cost approaches $4,500–$5,500 before physician consultation fees.

Johnson's published protocol includes continuous biomarker tracking via comprehensive quarterly blood panels, DEXA scans, VO2max testing, and epigenetic age clocks. Adding another $8,000–$12,000 annually. The peptide component represents one layer of a multi-modal intervention that also includes exercise, dietary restriction, sleep optimization, and pharmaceutical agents. Isolating the peptides' contribution to his documented biological age reduction is methodologically impossible. This is systems-level optimization, not single-intervention pharmacology.

If peptide protocols interest you as a research direction, raise storage requirements and reconstitution discipline with your research team before ordering compounds. These practical constraints determine whether a peptide regimen produces measurable outcomes or becomes an expensive series of injections with no verifiable biological effect. Real Peptides provides research-grade compounds with third-party purity verification for teams implementing peptide-based studies in controlled laboratory environments.